Cancer Biol Ther. 2010 Oct;10(7):658-64. Epub 2010 Oct 1.

Signaling pathways in renal cell carcinoma.

Source

Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

Abstract

Renal cell carcinoma (RCC), the most lethal type of genitourinary cancer, is generally resistant to chemotherapy and radiation therapy. Surgical excision of the tumor at a localized stage remains the mainstay for curative therapy. A number of drugs developed in recent years have shown limited to significant efficacy in treating RCC. These drugs act by blocking critical signaling pathways associated with RCC tumor growth and survival, and angiogenesis. Beyond well-validated signaling targets such as VHL, VEGFR and mTOR, additional pathways including HGF/c-MET and Wnt/β-catenin have emerged as important to RCC pathogenesis. Mutations in one or more components of these signaling networks may affect tumor response to therapy. This review summarizes the state of knowledge about signaling pathways in RCC and discusses the known genetic and epigenetic alterations that underlie dysregulation of these pathways.

PMID:: 20814228; [PubMed - indexed for MEDLINE]
PMCID:: PMC3093809

Free PMC Article

Images from this publication.See all images (1) Free text

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Kidney Cancer - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Molecular biology of renal cell carcinoma. [Clin Transl Oncol. 2006]
Review Molecular biology of renal cell carcinoma.
Mellado B, Gascón P. Clin Transl Oncol. 2006 Oct; 8(10):706-10.
Review Molecular basis for the treatment of renal cell carcinoma. [Clin Transl Oncol. 2010]
Review Molecular basis for the treatment of renal cell carcinoma.
Suárez C, Morales R, Muñoz E, Rodón J, Valverde CM, Carles J. Clin Transl Oncol. 2010 Jan; 12(1):15-21.
Review Sunitinib, sorafenib and mTOR inhibitors in renal cancer. [J BUON. 2007]
Review Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S, Bjelogrlic SK. J BUON. 2007 Sep; 12 Suppl 1:S151-62.
Review The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. [Kidney Int. 2009]
Review The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.
Clark PE. Kidney Int. 2009 Nov; 76(9):939-45. Epub 2009 Aug 5.
Review Pathways of dysregulation in renal cell carcinoma: rational approaches to development of novel treatment. [Clin Genitourin Cancer. 2006]
Review Pathways of dysregulation in renal cell carcinoma: rational approaches to development of novel treatment.
Khasawneh MK, Bukowski RM. Clin Genitourin Cancer. 2006 Dec; 5 Suppl 1:S7-S18.

See reviews... See all...

Cited by 2 PubMed Central articles

Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics. [Int J Mol Sci. 2012]
Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.
Ronca R, Benzoni P, De Luca A, Crescini E, Dell'era P. Int J Mol Sci. 2012; 13(4):5254-77. Epub 2012 Apr 24.
Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. [J Exp Clin Cancer Res. 2011]
Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma.
Ronkainen H, Hirvikoski P, Kauppila S, Vuopala KS, Paavonen TK, Selander KS, Vaarala MH. J Exp Clin Cancer Res. 2011 Sep 19; 30:84. Epub 2011 Sep 19.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Signaling pathways in renal cell carcinoma.
Signaling pathways in renal cell carcinoma.
Cancer Biol Ther. 2010 Oct ;10(7):658-64. Epub 2010 Oct 1 .

PubMed
Endovascular treatment or neurosurgical clipping of ruptured intracranial aneury...
Endovascular treatment or neurosurgical clipping of ruptured intracranial aneurysms: effect on angiographic vasospasm, delayed ischemic neurological deficit, cerebral infarction, and clinical outcome.
Stroke. 2010 Nov ;41(11):2519-24. Epub 2010 Sep 2 .

PubMed
No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondr...
No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas.
Am J Pathol. 2010 Oct ;177(4):1946-57. Epub 2010 Sep 2 .

PubMed
Spiroindolones, a potent compound class for the treatment of malaria.
Spiroindolones, a potent compound class for the treatment of malaria.
Science. 2010 Sep 3 ;329(5996):1175-80.

PubMed
Plasma vitamins B2, B6, and B12, and related genetic variants as predictors of c...
Plasma vitamins B2, B6, and B12, and related genetic variants as predictors of colorectal cancer risk.
Cancer Epidemiol Biomarkers Prev. 2010 Oct ;19(10):2549-61. Epub 2010 Sep 2 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: